Adrenocortical Carcinoma (Adrenal Cortex Cancer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Adrenocortical Carcinoma Pipeline Drugs Market
Adrenal cortex cancer (ACC) symptoms include high blood sugar and pressure, muscle weakness in the legs, excessive weight gain in the chest and abdomen, early signs of puberty in children, increased facial and body hair, particularly in females, and deepened voice in females. The Adrenocortical Carcinoma pipeline drugs market research report provides comprehensive information on the therapeutics under development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) and features dormant and discontinued projects.
Adrenocortical Carcinoma Pipeline Drugs Market Segmentation by Targets
Some of the targets of the Adrenocortical Carcinoma pipeline drugs market are Programmed Cell Death Protein 1, Cells Expressing CD276 Antigen, Fibroblast Growth Factor Receptor 1, Fibroblast Growth Factor Receptor 2, Fibroblast Growth Factor Receptor 3, Fibroblast Growth Factor Receptor 4, Mast/Stem Cell Growth Factor Receptor Kit, roto Oncogene Tyrosine Protein Kinase Receptor Ret, Vascular Endothelial Growth Factor Receptor 1, and Vascular Endothelial Growth Factor Receptor 2.
Adrenocortical Carcinoma Pipeline Drugs Market Analysis, by Targets
For more Adrenocortical Carcinoma pipeline drugs market target insights, download a free report sample
Adrenocortical Carcinoma Pipeline Drugs Market Segmentation by Mechanism of Actions
Some of the mechanism of actions of the Adrenocortical Carcinoma pipeline drugs market are Programmed Cell Death Protein 1 Antagonist, Cytotoxic To Cells Expressing CD276 Antigen, Fibroblast Growth Factor Receptor 1 Inhibitor, Fibroblast Growth Factor Receptor 2 Inhibitor, Fibroblast Growth Factor Receptor 3 Inhibitor, Fibroblast Growth Factor Receptor 4 Inhibitor, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Proto Oncogene Tyrosine Protein Kinase Receptor Ret Inhibitor, Vascular Endothelial Growth Factor Receptor 1 Inhibitor, and Vascular Endothelial Growth Factor Receptor 2 Inhibitor.
Adrenocortical Carcinoma Pipeline Drugs Market Analysis, by Mechanism of Actions
For more mechanism of action insights into the Adrenocortical Carcinoma pipeline drugs market, download a free report sample
Adrenocortical Carcinoma Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the Adrenocortical Carcinoma pipeline drugs market are intravenous, oral, intraperitoneal, intrathecal, subcutaneous, intracerebral, intravesical, and parenteral.
Adrenocortical Carcinoma Pipeline Drugs Market Analysis, by Routes of Administration
For more routes of administration insights into the Adrenocortical Carcinoma pipeline drugs market, download a free report sample
Adrenocortical Carcinoma Pipeline Drugs Market Segmentation by Molecule Types
The molecule types in the Adrenocortical Carcinoma pipeline drugs market are small molecule, monoclonal antibody, monoclonal antibody conjugated, oncolytic virus, and vaccine.
Adrenocortical Carcinoma Pipeline Drugs Market Analysis, by Molecule Types
For more molecule type insights into the Adrenocortical Carcinoma pipeline drugs market, download a free report sample
Competitive Landscape
Some of the key companies in the Adrenocortical Carcinoma pipeline drugs market are GSK plc, Merck & Co Inc, Pharma Mar SA, Bristol-Myers Squibb Co, Corcept Therapeutics Inc, Eisai Co Ltd, Enterome Bioscience SA, Exelixis Inc, Fusion Pharmaceuticals Inc, and Infinity Pharmaceuticals Inc.
Adrenocortical Carcinoma Pipeline Drugs Market Analysis, by Companies
To know more about the Adrenocortical Carcinoma pipeline drugs market companies, download a free report sample
Adrenocortical Carcinoma Pipeline Drugs Market Report Overview
Key Targets | Programmed Cell Death Protein 1, Cells Expressing CD276 Antigen, Fibroblast Growth Factor Receptor 1, Fibroblast Growth Factor Receptor 2, Fibroblast Growth Factor Receptor 3, Fibroblast Growth Factor Receptor 4, Mast/Stem Cell Growth Factor Receptor Kit, roto Oncogene Tyrosine Protein Kinase Receptor Ret, Vascular Endothelial Growth Factor Receptor 1, and Vascular Endothelial Growth Factor Receptor 2 |
Key Mechanism of Actions | Programmed Cell Death Protein 1 Antagonist, Cytotoxic To Cells Expressing CD276 Antigen, Fibroblast Growth Factor Receptor 1 Inhibitor, Fibroblast Growth Factor Receptor 2 Inhibitor, Fibroblast Growth Factor Receptor 3 Inhibitor, Fibroblast Growth Factor Receptor 4 Inhibitor, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Proto Oncogene Tyrosine Protein Kinase Receptor Ret Inhibitor, Vascular Endothelial Growth Factor Receptor 1 Inhibitor, and Vascular Endothelial Growth Factor Receptor 2 Inhibitor |
Key Routes of Administration | Intravenous, Oral, Intraperitoneal, Intrathecal, Subcutaneous, Intracerebral, Intravesical, and Parenteral |
Key Molecule Types | Small Molecule, Monoclonal Antibody, Monoclonal Antibody Conjugated, Oncolytic Virus, and Vaccine |
Leading Companies | GSK plc, Merck & Co Inc, Pharma Mar SA, Bristol-Myers Squibb Co, Corcept Therapeutics Inc, Eisai Co Ltd, Enterome Bioscience SA, Exelixis Inc, Fusion Pharmaceuticals Inc, and Infinity Pharmaceuticals Inc |
Scope
This report provides:
- A snapshot of the global therapeutic landscape of Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology).
- Reviews of pipeline therapeutics for Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- Reviews of key companies involved in Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) therapeutics and enlists all their major and minor projects.
- Evaluation of Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news related to pipeline therapeutics for Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Corcept Therapeutics Inc
Eisai Co Ltd
Enterome Bioscience SA
Exelixis Inc
Fusion Pharmaceuticals Inc
GSK plc
Infinity Pharmaceuticals Inc
Merck & Co Inc
Merck KGaA
Orphagen Pharmaceuticals Inc
Pharma Mar SA
Sanofi
Seneca Therapeutics Inc
Tempest Therapeutics Inc
Y-mAbs Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets of the Adrenocortical Carcinoma pipeline drugs market?
Some of the key targets of the Adrenocortical Carcinoma pipeline drugs market are Programmed Cell Death Protein 1, Cells Expressing CD276 Antigen, Fibroblast Growth Factor Receptor 1, Fibroblast Growth Factor Receptor 2, Fibroblast Growth Factor Receptor 3, Fibroblast Growth Factor Receptor 4, Mast/Stem Cell Growth Factor Receptor Kit, roto Oncogene Tyrosine Protein Kinase Receptor Ret, Vascular Endothelial Growth Factor Receptor 1, and Vascular Endothelial Growth Factor Receptor 2.
-
What are the key mechanism of actions of the Adrenocortical Carcinoma pipeline drugs market?
Some of the key mechanism of actions of the Adrenocortical Carcinoma pipeline drugs market are Programmed Cell Death Protein 1 Antagonist, Cytotoxic To Cells Expressing CD276 Antigen, Fibroblast Growth Factor Receptor 1 Inhibitor, Fibroblast Growth Factor Receptor 2 Inhibitor, Fibroblast Growth Factor Receptor 3 Inhibitor, Fibroblast Growth Factor Receptor 4 Inhibitor, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Proto Oncogene Tyrosine Protein Kinase Receptor Ret Inhibitor, Vascular Endothelial Growth Factor Receptor 1 Inhibitor, and Vascular Endothelial Growth Factor Receptor 2 Inhibitor.
-
What are the key routes of administration in the Adrenocortical Carcinoma pipeline drugs market?
The key routes of administration in the Adrenocortical Carcinoma pipeline drugs market are intravenous, oral, intraperitoneal, intrathecal, subcutaneous, intracerebral, intravesical, and parenteral.
-
What are the key molecule types in the Adrenocortical Carcinoma pipeline drugs market?
The molecule types in the Adrenocortical Carcinoma pipeline drugs market are small molecule, monoclonal antibody, monoclonal antibody conjugated, oncolytic virus, and vaccine.
-
Which are the leading companies in the Adrenocortical Carcinoma pipeline drugs market?
Some of the key companies in the Adrenocortical Carcinoma pipeline drugs market are GSK plc, Merck & Co Inc, Pharma Mar SA, Bristol-Myers Squibb Co, Corcept Therapeutics Inc, Eisai Co Ltd, Enterome Bioscience SA, Exelixis Inc, Fusion Pharmaceuticals Inc, and Infinity Pharmaceuticals Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.